Piaopiao Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Piaopiao Chen has a total of 217 co-authors. Here are the top co-authors by number of shared publications:
- Ke Huang
College of Chemistry and Material Science, Sichuan Normal University, Chengdu, Sichuan, 610068, China
24 shared publications Yue Wang
Sichuan University
24 shared publicationsPengjun Jiang
Sichuan University
20 shared publications- Binwu Ying
Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine Sichuan P. R. China
17 shared publications - Jia Geng
Department of Laboratory Medicine, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, China
12 shared publications Jie Chen
12 shared publications
Latest Publications
- 3 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (45) , 31093-31105
Dual DNA Nanomaterial-Regulated Homogeneous Immunoreaction-Enabled One-Step Electrochemical Analysis of Multiple Biomarkers in Clinical Samples
Homogeneous immunoassays offer a streamlined alternative to traditional heterogeneous methods by eliminating separation and washing steps. However, they are often hampered by low sensitivity, matrix interference, and limited multiplexing capability. Herein, we reported a dual DNA nanomaterial-based homogeneous electrochemical immunoassay that achieved ultrasensitive, one-step, simultaneous detection of multiple biomarkers. The system comprised a cyclic DNA nanomaterial (C-DNM) and a Y-shaped DNA nanosphere (Y-DNM) that coordinated Ag+ and Hg2+ via base mismatching, and antibodies were conjugated by the biotin–streptavidin system. Specific antigen–antibody binding could exert spatial steric hindrance on C-DNM, thereby triggering cascade metal ions release from Y-DNM and producing a second burst of signal amplification. This mechanism enabled detection limits down to the ag/mL level. Utilizing this strategy, we successfully quantified urinary ESAT-6 and LAM for tuberculosis, as well as PD-L1/MUC1-positive small extracellular vesicles (SEVs) and circulating tumor cells for lung cancer. The whole detection could be completed within 30 min. Clinical validation was taken in 60 samples, and the receiver operating curve analysis demonstrated good diagnostic accuracy, which showed strong correlation with clinical imaging findings. This dual DNA nanomaterial strategy provided a universal, rapid, and ultrasensitive tool for homogeneous immunoassay-based precision diagnostics of diseases.
- 3 November 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (45) , 31093-31105
Dual DNA Nanomaterial-Regulated Homogeneous Immunoreaction-Enabled One-Step Electrochemical Analysis of Multiple Biomarkers in Clinical Samples
Homogeneous immunoassays offer a streamlined alternative to traditional heterogeneous methods by eliminating separation and washing steps. However, they are often hampered by low sensitivity, matrix interference, and limited multiplexing capability. Herein, we reported a dual DNA nanomaterial-based homogeneous electrochemical immunoassay that achieved ultrasensitive, one-step, simultaneous detection of multiple biomarkers. The system comprised a cyclic DNA nanomaterial (C-DNM) and a Y-shaped DNA nanosphere (Y-DNM) that coordinated Ag+ and Hg2+ via base mismatching, and antibodies were conjugated by the biotin–streptavidin system. Specific antigen–antibody binding could exert spatial steric hindrance on C-DNM, thereby triggering cascade metal ions release from Y-DNM and producing a second burst of signal amplification. This mechanism enabled detection limits down to the ag/mL level. Utilizing this strategy, we successfully quantified urinary ESAT-6 and LAM for tuberculosis, as well as PD-L1/MUC1-positive small extracellular vesicles (SEVs) and circulating tumor cells for lung cancer. The whole detection could be completed within 30 min. Clinical validation was taken in 60 samples, and the receiver operating curve analysis demonstrated good diagnostic accuracy, which showed strong correlation with clinical imaging findings. This dual DNA nanomaterial strategy provided a universal, rapid, and ultrasensitive tool for homogeneous immunoassay-based precision diagnostics of diseases.
- 31 October 2026
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 472
Nanomachine-assisted one-pot electrochemical detection of dual lung cancer-associated ctDNA mutations
- 31 October 2026
- Published by Elsevier in Sensors and Actuators B: Chemical
- Vol. 472
Nanomachine-assisted one-pot electrochemical detection of dual lung cancer-associated ctDNA mutations
- Open Access
- 14 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77177
Controllable Cascade Aggregation Ion Programmed Nanomachines and Simple Isolation Enable Tumor‐Derived Small Extracellular Vesicles Detection for Enhanced Breast Cancer Assessment
Small extracellular vesicles (sEVs) carry biomolecules that reflect their cellular origin, making them attractive biomarkers for breast cancer assessment and human epidermal growth factor receptor 2 (HER2)‐status discrimination. However, existing methods involve lengthy isolation procedures and exhibit poor detection performance due to severe interference from excessive impurities. In this study, we constructed a dual‐target electrochemical (EC) sensing platform based on cascade aggregation effects. Combined with a facile filter‐based isolation strategy, this enables rapid and convenient dual‐marker (epithelial cell adhesion molecule (EpCAM) and HER2) analysis of breast cancer‐derived sEVs. This mechanism relies on the target‐triggered disassembly of DNA nanospheres to release Ag + /Hg 2+ for EC signaling. Subsequently, colistin specifically binds to G‐quadruplexes on unreacted nanospheres and induces their aggregation, sequestering background signal sources and preventing ion leakage. This noise‐silencing strategy improved matrix tolerance and reduced background leakage under a standardized diluted‐plasma workflow, enabling reliable detection of sEVs‐associated signals in filtration‐derived clinical samples. A proof‐of‐concept clinical study involving 63 breast cancer patients and 22 nonmalignant controls successfully demonstrated the platform's capability to distinguish cancer patients from controls. Furthermore, the platform achieved a 88.9% accuracy in differentiating HER2 status within this cohort. Overall, this streamlined “filtration‐to‐detection” platform offers a promising strategy for analyzing breast cancer‐specific sEVs signals and conducting exploratory HER2‐status assessments.
- 14 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (61) , e77177
Open AccessControllable Cascade Aggregation Ion Programmed Nanomachines and Simple Isolation Enable Tumor‐Derived Small Extracellular Vesicles Detection for Enhanced Breast Cancer Assessment
Small extracellular vesicles (sEVs) carry biomolecules that reflect their cellular origin, making them attractive biomarkers for breast cancer assessment and human epidermal growth factor receptor 2 (HER2)‐status discrimination. However, existing methods involve lengthy isolation procedures and exhibit poor detection performance due to severe interference from excessive impurities. In this study, we constructed a dual‐target electrochemical (EC) sensing platform based on cascade aggregation effects. Combined with a facile filter‐based isolation strategy, this enables rapid and convenient dual‐marker (epithelial cell adhesion molecule (EpCAM) and HER2) analysis of breast cancer‐derived sEVs. This mechanism relies on the target‐triggered disassembly of DNA nanospheres to release Ag + /Hg 2+ for EC signaling. Subsequently, colistin specifically binds to G‐quadruplexes on unreacted nanospheres and induces their aggregation, sequestering background signal sources and preventing ion leakage. This noise‐silencing strategy improved matrix tolerance and reduced background leakage under a standardized diluted‐plasma workflow, enabling reliable detection of sEVs‐associated signals in filtration‐derived clinical samples. A proof‐of‐concept clinical study involving 63 breast cancer patients and 22 nonmalignant controls successfully demonstrated the platform's capability to distinguish cancer patients from controls. Furthermore, the platform achieved a 88.9% accuracy in differentiating HER2 status within this cohort. Overall, this streamlined “filtration‐to‐detection” platform offers a promising strategy for analyzing breast cancer‐specific sEVs signals and conducting exploratory HER2‐status assessments.
- 28 July 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 312, 119076
Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer
- 28 July 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 312, 119076
Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer
- 13 June 2026
- Published by American Chemical Society (ACS) in ACS Nano
Dual MicroRNA Simultaneous One-Step Profiling via Filler-Mediated Quantum Dot DNA Nanospheres for Bladder Cancer Screening
Rapid and multiplexed detection of urinary microRNAs (miRNAs) is crucial for the noninvasive diagnosis and monitoring of bladder cancer. In this study, we develop a dual-channel fluorescence platform based on filler-mediated quantum dot-DNA nanospheres for simultaneous detection of miRNA-21 and miRNA-96. The nanospheres are constructed via a streptavidin–biotin cross-linked bidirectional hybridization chain reaction and compacted by phenyl-lactic acid, enabling high-density encapsulation of distinct QDs. Upon target miRNA recognition, a strand-displacement cascade triggers nanosphere disassembly and QDs release, restoring well-resolved fluorescence at 500 and 624 nm. This enzyme-free, extraction-free assay is completed in 40 min. It achieves attomolar-level sensitivity, with detection limits of 30 aM for miRNA-21 and 40 aM for miRNA-96, while maintaining high selectivity against mismatched and nontarget miRNAs. Clinical validation using urine samples from 45 patients with bladder cancer, 22 patients with other urological diseases, and 20 healthy controls indicated strong concordance with quantitative polymerase chain reaction. Integrated dual-miRNA analysis significantly enhanced diagnostic performance, yielding 91.0% sensitivity, 80.0% specificity, and an area under the curve of 0.91. The platform provides a rapid tool for noninvasive miRNA profiling, with potential to distinguish bladder cancer from healthy individuals and other urological diseases, thereby improving bladder-cancer screening, stratification, and recurrence monitoring.
- 13 June 2026
- Published by American Chemical Society (ACS) in ACS Nano
Dual MicroRNA Simultaneous One-Step Profiling via Filler-Mediated Quantum Dot DNA Nanospheres for Bladder Cancer Screening
Rapid and multiplexed detection of urinary microRNAs (miRNAs) is crucial for the noninvasive diagnosis and monitoring of bladder cancer. In this study, we develop a dual-channel fluorescence platform based on filler-mediated quantum dot-DNA nanospheres for simultaneous detection of miRNA-21 and miRNA-96. The nanospheres are constructed via a streptavidin–biotin cross-linked bidirectional hybridization chain reaction and compacted by phenyl-lactic acid, enabling high-density encapsulation of distinct QDs. Upon target miRNA recognition, a strand-displacement cascade triggers nanosphere disassembly and QDs release, restoring well-resolved fluorescence at 500 and 624 nm. This enzyme-free, extraction-free assay is completed in 40 min. It achieves attomolar-level sensitivity, with detection limits of 30 aM for miRNA-21 and 40 aM for miRNA-96, while maintaining high selectivity against mismatched and nontarget miRNAs. Clinical validation using urine samples from 45 patients with bladder cancer, 22 patients with other urological diseases, and 20 healthy controls indicated strong concordance with quantitative polymerase chain reaction. Integrated dual-miRNA analysis significantly enhanced diagnostic performance, yielding 91.0% sensitivity, 80.0% specificity, and an area under the curve of 0.91. The platform provides a rapid tool for noninvasive miRNA profiling, with potential to distinguish bladder cancer from healthy individuals and other urological diseases, thereby improving bladder-cancer screening, stratification, and recurrence monitoring.
- 23 May 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 309, 118847
Mycobacterium tuberculosis urine ESAT-6 antigen homogeneous immunoassay through spatial confinement and cascade material amplification
- 23 May 2026
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 309, 118847
Mycobacterium tuberculosis urine ESAT-6 antigen homogeneous immunoassay through spatial confinement and cascade material amplification
- Open Access
- 1 May 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (48) , e75631
Precisely Controllable Y‐Shaped DNA Nanomachine‐Immunoassay System: Noninvasive Monitoring of Tumor Progression and Metastasis
Herein, we developed a DNA scaffold‐mediated Y‐shaped DNA nanomachine immunoassay system (DYN@IA) that enables a homogeneous electrochemical immunoassay for the simultaneous detection of epithelial and mesenchymal circulating tumor cells, applicable to early cancer diagnosis and monitoring. The double Y‐shaped DNA design facilitated the self‐assembly of metal ion‐mediated DNA nanomachines, forming stable and controllable functional nanomachines for the recognition of heterogeneous CTCs. Antigen‐antibody binding formed steric hindrance and exerted local tension on the DNA scaffolds through the biotin‐streptavidin system, triggering conformational changes in the double‐stranded DNA, and releasing Ag + and Hg 2+ . Finally, the practical validation was conducted using primary lung cancer cells (pre‐ and post‐metastasis) and the surface targets epithelial cell adhesion molecule and vimentin. The results indicated that simultaneous detection of different CTCs was achieved within 45 min, with a limit of detection down to the single‐cell level. Additionally, the method was successfully applied to 145 clinical samples for lung cancer early screening and identification of distant metastasis (achieving sensitivity and specificity of 88% and 96%), with results highly consistent with imaging findings and pathology diagnoses. The DYN@IA design outperformed conventional immunoassays by significantly shortening reaction time while improving sensitivity and signal‐to‐noise ratio, providing insights for tumor screening and monitoring.
- 1 May 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (48) , e75631
Open AccessPrecisely Controllable Y‐Shaped DNA Nanomachine‐Immunoassay System: Noninvasive Monitoring of Tumor Progression and Metastasis
Herein, we developed a DNA scaffold‐mediated Y‐shaped DNA nanomachine immunoassay system (DYN@IA) that enables a homogeneous electrochemical immunoassay for the simultaneous detection of epithelial and mesenchymal circulating tumor cells, applicable to early cancer diagnosis and monitoring. The double Y‐shaped DNA design facilitated the self‐assembly of metal ion‐mediated DNA nanomachines, forming stable and controllable functional nanomachines for the recognition of heterogeneous CTCs. Antigen‐antibody binding formed steric hindrance and exerted local tension on the DNA scaffolds through the biotin‐streptavidin system, triggering conformational changes in the double‐stranded DNA, and releasing Ag + and Hg 2+ . Finally, the practical validation was conducted using primary lung cancer cells (pre‐ and post‐metastasis) and the surface targets epithelial cell adhesion molecule and vimentin. The results indicated that simultaneous detection of different CTCs was achieved within 45 min, with a limit of detection down to the single‐cell level. Additionally, the method was successfully applied to 145 clinical samples for lung cancer early screening and identification of distant metastasis (achieving sensitivity and specificity of 88% and 96%), with results highly consistent with imaging findings and pathology diagnoses. The DYN@IA design outperformed conventional immunoassays by significantly shortening reaction time while improving sensitivity and signal‐to‐noise ratio, providing insights for tumor screening and monitoring.